1. Introduction
===============

Galectin-3 is a member of the family of β-galactoside-binding proteins that bind to the carbohydrate portion of cellsurface glycoproteins and glycolipids \[[@B001]\]. Galectin-3 has a chimera-type structure consisting of three different structural domains: a short NH2-terminal domain of 12 amino acids that contains a serine phosphorylation site; a repeated collagen-like sequence that rich in glycine, tyrosine, and proline amino acid residues, which serves as a substrate for matrix metalloproteinases (MMPs); and a COOHterminal carbohydrate recognition domain \[[@B001] - [@B003]\]. Galectin-3 is a multifunctional oncogene \[[@B001]\], which regulates cell growth \[[@B004]\], adhesion \[[@B005]\], proliferation \[[@B006]\], angiogenesis \[[@B007]\], and apoptosis \[[@B008]\].

Many studies have shown that galectin-3 regulates cancer cell proliferation. Galectin-3-stimulated cell proliferation of IMR-90 human lung fibroblasts \[[@B006]\]; a decrease of galectin-3 expression in activated T lymphocytes paralleled a downregulation or even a blocking of proliferation \[[@B009]\]; and the introduction of galectin-3 cDNA caused human lymphoma Jurkat T cells to grow faster \[[@B010]\]. A recent report provided evidence that downregulation of galectin-3 led to diminished human colon cancer cell proliferation via modulation of the hete-rogeneous nuclear ribonucleoprotein Q (hnRNP Q) level \[[@B011]\].

Overexpression of galectin-3 has been reported in gastric cancer \[[@B012]\]. Positive galectin-3 expression was observed in 84% of gastric cancer cases. In enhanced cells of a cancerous lesion, 48% showed stronger nuclear immunoreactivity than a cytoplasmic one whereas adjacent epithelial cells showed little or weak nuclear immunoreactivity \[[@B012]\]. In addition, decreased galectin-3 expression was found in breast \[[@B013]\], ovary \[[@B014]\], prostate \[[@B015]\], epithelial skin cancer \[[@B016]\], and head-and-neck squamous cell carcinomas \[[@B017]\] than in corresponding normal tissue.

HangAmDan (HAD)-B consists of eight species of Korean medicinal plants and animals (Table[1](#T001){ref-type="table"}), and is an upgraded version of HangAmDan (HAD) used traditionally for solid masses, which also shows anti-angiogenic activity \[[@B018]\]. A mixture of these plants has been shown to exert strong anticancer activity against solid tumors, including pancreatic, lung, colorectal, and stomach cancers. Additionally, anti-angiogenesis effects and inhibition of cancer cell proliferation and metastasis have been reported \[[@B019]\]. In particular, case reports observed with HAD have been selected as part of the National Cancer Institute's Best Case Series Program \[[@B020]\]. HAD-B has shown efficacy in inhibiting migration and proliferation of human umbilical vein endothelial cells and in limiting the formation of capillary tube structures \[[@B021]\]. Furthermore, a safety evaluation of HAD-B has revealed no side-effects in both healthy subjects and cancer patients \[[@B022]\].

Even though a number of studies have reported the functions of galectin-3 in many types of cancer, the mechanisms by which galectin-3 is involved in cell proliferation are not yet fully understood, especially in human colon cancer cells. In the present study we report that γ-aminobutyric acid B receptor 1 (GABABR1) expression is linked to galectin-3 in human colon cancer cell line, and we discuss the effect of galectin-3- independent down-regulation of GABABR1 by treatment with Korean herbal extract HAD-B in human colon cancer cells.

2. Materials and methods
========================

2.1. Human colon cancer cell lines
----------------------------------

Human colon cancer cell lines, SNU-61, SNU-81, SNU-769B, SNU-C4 and SNU-C5, were obtained from the Korean Cell Line Bank (Seoul, Korea).

2.2. Preparation of water extract of HAD-B
------------------------------------------

###### Ingredients of HAD-B

  Scientific name                     Relative amount (mg)
  ----------------------------------- ----------------------
  *Panax notoginseng Radix*           84.0
  *Cordyceps Militaris*               64.0
  *Santsigu Tuber*                    64.0
  *Ginseng Radix*                     64.0
  *Bovis Calculus*                    64.0
  *Margarita*                         64.0
  *Bostaurus var.domesticus Gmelin*   48.0
  *Commiphora myrrha*                 48.0
  Total amount (1 capsule)            500.0

HAD-B was provided from the East-West Cancer Center of Dunsan Oriental Medical Hospital, Daejeon University, Daejeon, Korea (Table [1](#T001){ref-type="table"}). The water extract of HAD-B was prepared by extracting HAD-B powder with 10-times (v/w) the amount of distilled water at room temperature for 24 hrs. The extract was centrifuged at 1000×g for 30 mins and was then filtered and lyophilized. The extract powder was dissolved directly in distilled water.

2.3. 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay
-------------------------------------------------------------------------------

A colorimetric assay using tetrazolium salt, MTT, was used to assess cell proliferation after galectin-3 suppression. MTT assays were performed as described in a previous report \[[@B011]\]. Briefly, equal numbers of cells were incubated in each well in 0.18 ml of culture medium to which 0.02 ml of 10 × 5-FU (Choongwae Pharma Corporation), HAD-B, GABA or PBS (for untreated 100% survival control) had been added. After 4 days of culture, 0.1 mg of MTT was added to each well and incubated at 37°C for a further 4 hrs. Plates were centrifuged at 450 × g for 5 mins at room temperature, and the medium was removed. Dimethyl sulfoxide (0.15 ml) was added to each well to solubilize the crystals, and plates were immediately read at 540 nm by using a scanning multiwell spectrometer (Bio-Tek Instruments Inc., Winooski, VT). All experiments were performed three times, and the IC50 (μg/ml) values are presented as means ± standard deviations.

2.4. Western blot analysis
--------------------------

Western blot analyses were performed as described in a previous report \[[@B011]\]. Primary antibodies against galectin-3 (Abcam, Cambridge, UK), γ-aminobutyric acid B receptor 1 (GABABR1) (Abcam) and actin (Abcam) (1:1,000) were used.

2.5. Immunoprecipitation
------------------------

All procedures were performed at 4°C unless otherwise specified. Approximately 10^7^ cells in 1 ml of cold 1 × radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitors (Roche Diagnostics) were incubated on ice for 30 mins with occasional mixing. Cell lysates were centrifuged at 12,000 × g for 10 mins, and the supernatant was collected carefully without disturbing the pellet. The supernatant was mixed with primary antibody against either galectin-3 (Abcam) or GABABR1 (Abcam) and was incubated for 2 hrs on a rocking platform. Prepared protein G sepharose beads (GE Health Care Life Sciences) were added and further incubated on ice for 1 hrs on a rocking platform. The mixture was centrifuged at 10,000 g for 30 s, and the supernatant was removed completely. Protein G sepharose beads were washed 5 times with 1 ml of cold 1 × RIPA to minimize the background. Next, 100 μl of 2 × sodium dodecyl sulfate (SDS) sample buffer was added to the bead pellets and heated to 100°C for 10 mins. After boiling, immunoprecipitates were centrifuged at 10000 × g for 5 mins, and the supernatant was collected for the Western blot analysis.

2.6. Intracellular cAMP measurement
-----------------------------------

The intracellular cAMP for human colon cancer cells was determined by using a cAMP Direct Immunoassay Kit (Abcam), as recommended by the manufacturer.

2.7. RNA preparation and Affymetrix GeneChip hybridization
----------------------------------------------------------

Total RNA was extracted using Trizol reagent (Life Technologies, Inc., Carlsbad, CA), according to the manufacturer's instructions. Genes expressed in the chemosensitive and chemoresistant groups were analyzed on a high-density oligonucleotide microarray (HG-U133A; Affymetrix, Santa Clara, CA) containing 22,283 transcripts. Target preparation and microarray processing procedures were performed, following the Affymetrix GeneChip Expression Analysis Manual (Affymetrix). Briefly, total RNA extracted was purified with an RNeasy kit (Qiagen). Double-stranded cDNA was synthesized from total RNA (20 μg) with SuperScript II reverse transcriptase (Life Technologies, Inc. Rockville, MD) and a T7-(dT)24 primer (Metabion, Germany). Biotinylated cRNA was synthesized from double-stranded cDNA by using a RNA Transcript Labeling kit (Enzo Life Sciences, Farmingdale, NY), purified, and fragmented. Fragmented cRNA was hybridized to the oligonucleotide microarray, which was washed and stained with streptavidinphycoerythrin. Scanning was performed with an Agilent Microarray Scanner (Agilent Technologies, Santa Clara, CA).

2.8. Affymetrix GeneChip data analysis
--------------------------------------

A GeneChip analysis was performed based on the Affymetrix GeneChip Manual (Affymetrix) with Data Mining Tool (DMT) 2.0 and Microarray Database software. All genes represented on the GeneChip were globally normalized and scaled to a signal intensity of 500. Fold changes were calculated by comparing transcripts between the cell lines tested. The DMT 2.0 software employed changed calls (increased or decreased) to analyze the expression of a particular transcript statistically and to determine whether it had been relatively increased, decreased or remained unchanged. After filtration through a \"present\" call (*p*〈0.05), a transcript was considered differentially expressed at a fold change of greater than 2.0.

2.9. Real-time quantitative reverse transcription polymerase chain reaction
---------------------------------------------------------------------------

Four genes (ELF3, AXIN2, ENO2 and SACS) were selected for real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) for validation of the microarray data. Using the SuperScript Pre-amplification System for first strand cDNA synthesis, 5 mg of total RNA was used for creation of singlestranded cDNA (Life Technologies). The cDNA was diluted and quantitatively equalized for PCR amplification. For real-time qRT-PCR, the ABI Prism 7900 sequence detection system (Applied Biosystems) was used. AccuPower GreenStar PCR Master Mix (Bioneer Corporation, Daejeon, Korea) was used for each PCR reaction, and the GAPDH gene was simultaneously run as a control and was used for normalization. Non-template-control wells without cDNA were included as negative controls. Each test sample was run in triplicate. The primer sets for PCR amplification were designed as follows: ELF3-F: 5'-TGAGCTGCTGGAGAAGGATG- 3', ELF3-R: 5'-CCCTTCTTGCAGTCACGAAA- 3', AXIN2-F: 5'-AATCATTCGGCCACTGTTCA-3', AXIN2-R: 5'- CACAGGCAAACTCATCGCTT-3', ENO2-F: 5'-CTGATGCTGGAGTTGGATGG- 3', ENO2-R: 5'-CCATTGATCACGTTGAAGGC-3', SACS-F: 5'-CCATTTGTTGGCATTTTTGG-3', and SACS-R: 5'- CGCTCATGTTTCAGTGCCTT-3'. Following the standard curve method, the expressed quantities of the examined genes were determined using the standard curves and the CT values and were normalized using the GAPDH expression quantities.

3. Results
==========

3.1. Galectin-3 expression related to 5-FU susceptibility in human colon cancer cells
-------------------------------------------------------------------------------------

To confirm the correlation between galectin-3 expression and 5-FU susceptibility in human colon cancer cells, we performed Western blot and MTT analyses on three human colon cancer cell lines, SNU-769B, SNU-C4 and SNU-C5. 5-FU susceptibility showed a decreasing tendency that depended on both the transcriptional (Fig [1](#F001){ref-type="fig"} A) and the translational (Fig [1](#F001){ref-type="fig"} Ba) levels of galectin-3. To cluster the genes showing positively or negatively correlated expression with galectin-3, we employed SNU-61, which had almost the same 5-FU susceptibility as SNU-769B, in a high-throughput gene expression profiling experiment (Fig. [1](#F001){ref-type="fig"} B & Tables [2](#T002){ref-type="table"}, [3](#T003){ref-type="table"}). Figure [1](#F001){ref-type="fig"} Ba shows an example of 19 genes clustered in a galectin-3 expression pattern, which was confirmed by real-time PCR (Fig [1](#F001){ref-type="fig"} Bb). The top 50 down- and up-regulated genes in SNU-C5, compared to SNU-769B, are listed in Tables [2](#T002){ref-type="table"}, [3](#T003){ref-type="table"} respectively.

![Galectin-3 expression correlated with 5-FU susceptibility in human colon cancer cell lines and gene expression profiling linked to galectin-3.](2093-6966-v15-n03-019-g001){#F001}

3.2. Galectin-3-dependent γ-aminobutyric acid B receptor 1 (GABABR1) expression in human colon cancer cells
-----------------------------------------------------------------------------------------------------------

Although the genes listed in Tables [2](#T002){ref-type="table"}, [3](#T003){ref-type="table"} contain γ-aminobutyric acid B receptor 1 (GABABR1), its expression was positi-vely correlated with galectin-3 as previously reported (Fig [2](#F002){ref-type="fig"} A) \[[@B011]\]. GABABR1 expression at the translational level was highest in SNU-769B among the three human colon cancer cell lines tested (Fig [2](#F002){ref-type="fig"} B). To validate the interaction between galectin-3 and GABABR1, we performed reverse immunoprecipitation: however, galectin-3 did not form a complex with GABABR1 (Fig [2](#F002){ref-type="fig"} C).

![Gene and protein expressions of GABABR1 positively linked to galectin-3 expression.](2093-6966-v15-n03-019-g002){#F002}

3.3. Galectin-3-independent down-regulation of GABABR1 protein by HAD-B in human colon cancer cells
---------------------------------------------------------------------------------------------------

To check the effect of HAD-B treatment on the expression level of galectin-3 and GABABR1, we cultured SNU-C4 with modest expression of galectin-3 and GABABR1 in the presence of HADB, and we performed a Western blot analysis. At 96 hrs after treatment with 1 mg/ml HAD-B, expression of GABABR1 was reduced, but galectin-3 did not show any expressional change (Fig [3](#F003){ref-type="fig"} A).

3.4. GABABR1-mediated proliferation of human colon cancer cells suppressed by HAD-B treatment
---------------------------------------------------------------------------------------------

Treatment with γ-aminobutyric acid (GABA) in the culture medium promoted proliferation of the human colon cancer cell line SNU-C4 (Fig [3](#F003){ref-type="fig"} B). At 48 hrs after treatment with GABA, cell proliferation was increased up to \~50% compared to nonetreated controls, but rate of increase of proliferation was not maintained (Fig [3](#F003){ref-type="fig"} B). HAD-B significantly decreased cell proliferation at 48 hrs after treatment compared to the control, but the suppressed proliferation had recovered at 96 hrs (Fig [3](#F003){ref-type="fig"} B). Cells co-treated with GABA and HAD-B showed almost the same pattern of proliferation as that of the control (Fig [3](#F003){ref-type="fig"} B). Either GABA or HAD-B treatment slightly increased the intracellular cAMP in SNU-C4 compared to that in the nontreated control (Fig [3](#F003){ref-type="fig"} C).

![Reduced GABABR1 expression and suppressed cell proliferation of SNU-C4 by treatment with HAD-B.](2093-6966-v15-n03-019-g003){#F003}

###### Top 50 down-regulated genes in SNU-C5 compared to SNU-769B

  Probe Set ID   Gene Symbol   SNU- 769A   SNU- C4   SNU- C5   FC     GO Biological Process Term                                                          GO Cellular Component Term              GO Molecular Function Term
  -------------- ------------- ----------- --------- --------- ------ ----------------------------------------------------------------------------------- --------------------------------------- ---------------------------------------------------
  8101893        ADH1C         2263        1125      14        -7.3   alcohol metabolic process                                                           cytoplasm                               alcohol dehydrogenase activity, zinc-dependent
  7989501        CA12          2428        789       26        -6.5   one-carbon compound metabolic process                                               membrane                                carbonate dehydratase activity
  8022692        DSC3          904         35        10        -6.5   cell adhesion                                                                       membrane fraction                       calcium ion binding
  7979658        GPX2          2129        1408      24        -6.5   response to oxidative stress                                                        cytoplasm                               glutathione peroxidase activity
  7919055        HMGCS2        2091        1229      28        -6.2   acetyl-CoA metabolic process                                                        mitochondrion                           hydroxymethylglutaryl-CoA synthase activity
  8036591        LGALS4        5079        4762      69        -6.2   cell adhesion                                                                       cytosol                                 sugar binding
  7928770        PCDH21        1522        291       21        -6.2   homophilic cell adhesion                                                            membrane                                calcium ion binding
  7953200        CCND2         2210        60        37        -5.9   regulation of progression through cell cycle                                        nucleus                                 protein binding
  7928766        C10orf99      1970        493       33        -5.9                                                                                                                               
  8138392        AGR3          292         174       6         -5.7                                                                                                                               
  7919984        SELENBP1      2409        1499      54        -5.5                                                                                                                               selenium binding
  8174654        KLHL13        650         164       16        -5.3                                                                                                                               protein binding
  7967107        C12orf27      367         229       9         -5.3                                                                                                                               
  8161884        PRUNE2        396         230       12        -5.1                                                                                                                               
  8106354        IQGAP2        704         95        22        -5.0   signal transduction                                                                 intracellular                           actin binding
  8134339        PEG10         658         28        21        -5.0   negative regulation of transforming growth factor beta receptor signaling pathway   cytoplasm                               nucleic acid binding
  8135378        PRKAR2B       543         85        18        -4.9   protein amino acid phosphorylation                                                  cAMP-dependent protein kinase complex   nucleotide binding
  8091283        PLOD2         358         98        13        -4.8   protein modification process                                                        endoplasmic reticulum                   iron ion binding
  8128123        RRAGD         311         58        12        -4.7                                                                                       nucleus                                 nucleotide binding
  7983606        EID1          759         568       30        -4.7   negative regulation of transcription from RNA polymerase II promoter                cellular component                      protein binding
  8100734        UGT2B17       125         6         5         -4.6   metabolic process                                                                   membrane fraction                       glucuronosyltransferase activity
  8080964        PPP4R2        293         130       12        -4.6   protein modification process                                                        centrosome                              protein binding
  8151592        CA1           256         23        11        -4.6   one-carbon compound metabolic process                                               cytoplasm                               carbonate dehydratase activity
  8101757        GPRIN3        711         256       31        -4.5                                                                                                                               
  7926545        PLXDC2        499         87        22        -4.5   multicellular organismal development                                                membrane                                receptor activity
  7916185        ZCCHC11       266         262       12        -4.5                                                                                       intracellular                           nucleic acid binding
  8008172        B4GALNT2      693         38        30        -4.5   UDP-N-acetylgalactosamine metabolic process                                         membrane                                acetylgalactosaminyltransferase activity
  8040374        FAM84A        998         492       44        -4.5                                                                                                                               
  8168589        ZNF711        378         106       19        -4.4   regulation of transcription, DNA-dependent                                          intracellular                           DNA binding
  8043981        IL1R2         663         54        33        -4.3   immune response                                                                     membrane                                receptor activity
  7923578        FMOD          359         74        18        -4.3   transforming growth factor beta receptor complex assembly                           proteinaceous extracellular matrix      protein binding
  8138553        FAM126A       210         69        11        -4.3   biological process                                                                  cellular component                      signal transducer activity
  8077323        CNTN4         168         11        10        -4.1   cell adhesion                                                                       plasma membrane                         protein binding
  7999553        FLJ11151      337         207       20        -4.1                                                                                                                               hydrolase activity
  7940565        FADS2         502         380       31        -4.0   lipid metabolic process                                                             membrane fraction                       iron ion binding
  7951554        RDX           259         67        16        -4.0   cytoskeletal anchoring                                                              cytoplasm                               actin binding
  8044212        SULT1C2       215         39        13        -4.0   amine metabolic process                                                             cytoplasm                               sulfotransferase activity
  7903742        GSTM2         946         183       59        -4.0   metabolic process                                                                                                           glutathione transferase activity
  7937335        IFITM1        402         343       25        -4.0   regulation of progression through cell cycle                                        plasma membrane                         receptor signaling protein activity
  8041383        LTBP1         470         213       30        -4.0   biological process                                                                  proteinaceous extracellular matrix      transforming growth factor beta receptor activity
  8142171        SLC26A3       185         18        12        -4.0   transport                                                                           membrane fraction                       transcription factor activity
  7951789        FAM55D        318         209       21        -3.9                                                                                                                               
  8078544        MLH1          155         121       10        -3.9   mismatch repair                                                                     nucleus                                 single-stranded DNA binding
  8111772        DAB2          344         72        23        -3.9   cellular morphogenesis during differentiation                                       coated pit                              protein C-terminus binding
  8094988        FLJ21511      270         75        18        -3.9                                                                                                                               
  7918223        C1orf59       122         101       8         -3.9                                                                                                                               
  8095110        KIT           160         29        11        -3.9   protein amino acid dephosphorylation                                                external side of plasma membrane        nucleotide binding
  8125149        SLC44A4       1306        1163      88        -3.9                                                                                       membrane                                
  8178653        NEU1          1306        1163      88        -3.9   metabolic process                                                                   lysosome                                exo-alpha-sialidase activity
  8179861        NEU1          1306        1163      88        -3.9   metabolic process                                                                   lysosome                                exo-alpha-sialidase activity

FC: Fold-change was calculated from the signal Log ratio value.

###### Top 50 up-regulated genes in SNU-C5, compared to SNU-769B

  Probe Set ID   Gene Symbol   SNU- 769A   SNU- C4   SNU- C5   FC    GO Biological Process Term                                               GO Cellular Component Term           GO Molecular Function Term
  -------------- ------------- ----------- --------- --------- ----- ------------------------------------------------------------------------ ------------------------------------ ---------------------------------------------------------------
  7954330        SLCO1B3       6           551       921       7.3   ion transport                                                            integral to plasma membrane          transporter activity
  7959856        PIWIL1        11          17        834       6.3   multicellular organismal development                                     cytoplasm                            single-stranded RNA binding
  7954090        EMP1          23          51        1597      6.1   multicellular organismal development                                     membrane fraction                    
  7954344        LST-3TM12     14          236       875       6.0   transport                                                                membrane                             transporter activity
  8026490        LOC729642     29          34        1815      5.9                                                                                                                 
  8108217        TGFBI         36          105       2089      5.9   cell adhesion                                                            proteinaceous extracellular matrix   integrin binding
  8176026        FLNA          67          699       2852      5.4   cell motility                                                            nucleus                              actin binding
  7954356        SLCO1B1       10          55        327       5.1   ion transport                                                            membrane fraction                    transporter activity
  8124437        HIST1H3F      45          49        1482      5.0   nucleosome assembly                                                      nucleosome                           DNA binding
  7997139        CALB2         33          35        1020      5.0                                                                                                                 calcium ion binding
  8102950        INPP4B        25          131       786       5.0   signal transduction                                                                                           phosphatidylinositol-3, 4-bisphosphate 4-phosphatase activity
  8095728        EREG          62          230       1896      4.9   regulation of progression through cell cycle                             extracellular space                  epidermal growth factor receptor binding
  8155849        ANXA1         65          980       1942      4.9   lipid metabolic process                                                  cornified envelope                   phospholipase inhibitor activity
  8089082        DCBLD2        131         308       3841      4.9   cell adhesion                                                            integral to plasma membrane          protein binding
  8140668        SEMA3A        36          190       1067      4.9   multicellular organismal development                                     extracellular region                 chemorepellant activity
  7920128        S100A11       41          806       1209      4.9   signal transduction                                                      ruffle                               calcium ion binding
  8098470        WWC2          13          20        358       4.8                                                                                                                 
  8067233        TMEPAI        50          115       1311      4.7   androgen receptor signaling pathway                                      membrane                             molecular function
  7909789        TGFB2         18          22        440       4.6   cell morphogenesis                                                       extracellular region                 beta-amyloid binding
  8015016        TNS4          42          240       1027      4.6   apoptosis                                                                cytoskeleton                         actin binding
  8095744        AREG          44          240       1080      4.6   cell-cell signaling                                                      extracellular space                  cytokine activity
  8021442        ZNF532        28          73        673       4.6                                                                            intracellular                        nucleic acid binding
  7933312        LOC653110     27          29        648       4.6                                                                                                                 
  7981514        AHNAK2        22          42        532       4.6                                                                                                                 protein binding
  8027778        FXYD5         65          433       1459      4.5   ion transport                                                            membrane                             actin binding
  7908072        LAMC2         73          317       1591      4.4   cell adhesion                                                            basement membrane                    protein binding
  8075310        LIF           54          56        1139      4.4   immune response                                                          extracellular region                 cytokine activity
  8138466        7A5           61          316       1226      4.3                                                                                                                 
  7986446        ALDH1A3       88          114       1741      4.3   alcohol metabolic process                                                                                     3-chloroallyl aldehyde dehydrogenase activity
  8041179        CLIP4         18          20        356       4.3                                                                                                                 
  8124413        HIST1H4D      63          338       1234      4.3                                                                                                                 
  7924029        LAMB3         77          169       1473      4.3   electron transport                                                       proteinaceous extracellular matrix   structural molecule activity
  8129379        ECHDC1        38          685       717       4.3   metabolic process                                                                                             catalytic activity
  7945321        LOC89944      33          510       625       4.2   carbohydrate metabolic process                                           beta-galactosidase complex           catalytic activity
  8179731        HLA-C         153         616       2862      4.2   ciliary or flagellar motility                                            axonemal dynein complex              microtubule motor activity
  8064613        SLC4A11       72          239       1300      4.2   anion transport                                                          membrane                             inorganic anion exchanger activity
  8167185        TIMP1         215         857       3816      4.1   multicellular organismal development                                     extracellular region                 enzyme inhibitor activity
  8120602        OGFRL1        28          141       438       4.0                                                                            membrane                             receptor activity
  8178489        HLA-C         190         730       2990      4.0   ciliary or flagellar motility                                            axonemal dynein complex              microtubule motor activity
  8060758        PRNP          108         486       1632      3.9   copper ion homeostasis                                                   cytoplasm                            copper ion binding
  8178498        HLA-B         164         517       2463      3.9   antigen processing and presentation of peptide antigen via MHC class I   cellular component                   molecular function
  8124911        HLA-B         131         408       1955      3.9   antigen processing and presentation of peptide antigen via MHC class I   cellular component                   molecular function
  7973985        MIPOL1        9           92        134       3.9                                                                                                                 
  7944722        STS-1         32          58        473       3.9                                                                            nucleus                              
  8124901        HLA-C         205         724       2974      3.9   ciliary or flagellar motility                                            axonemal dynein complex              microtubule motor activity
  8095736        LOC727738     43          170       615       3.8                                                                                                                 
  8091411        TM4SF1        38          220       538       3.8   biological process                                                       integral to plasma membrane          molecular function
  7917875        F3            78          87        1078      3.8   immune response                                                          plasma membrane                      transmembrane receptor activity
  8092726        CLDN1         57          195       772       3.8   cell adhesion                                                            integral to plasma membrane          structural molecule activity
  8126820        GPR110        16          20        217       3.8   signal transduction                                                      membrane                             receptor activity

FC: Fold-change was calculated from the signal Log ratio value.

4. Discussion
=============

Colon cancer causes almost a half million deaths every year \[[@B023]\]. In the past 3 decades, 5-fluorouracil (5-FU) chemotherapy and 5-FU-based chemotherapy have been the mainstream in adjuvant treatment of colon cancer \[[@B024]\]; however, partial or complete responses of colon cancer to 5-FU are generally followed by eventual tumor re-growth \[[@B025]\]. Numerous studies have focused on identifying the mechanisms and key molecules involved in natural or acquired 5-FU resistance. Nevertheless, conclusive and consistent results have not been obtained so far. A recent proteome approach identified galectin-3 as a protein affecting 5-FU resistance and the proliferation rate of human colon cancer cells \[[@B011]\]. Our present study confirmed the correlation between galectin-3 expression and 5-FU susceptibility in three human colon cancer cell lines. 5-FU susceptibility of human colon cancer cells was different depending on both the transcriptional and the translational levels of galectin-3 (Fig [1](#F001){ref-type="fig"}A,B). Because the identification of genes showing positively or negatively correlated expression with galectin-3 can provide further information on how galectin-3 regulates proliferation of human colon cancer cells, a high-density oligonucleotide microarray was performed. From this transcriptional analysis, we were able to list the genes down- and up-regulated based on the level of galectin-3 expression (Fig. [1](#F001){ref-type="fig"}B, Tables[2](#T002){ref-type="table"}, [3](#T003){ref-type="table"}). Though γ-aminobutyric acid B receptor 1 (GABABR1) was not in the top 50 genes linked to galectin-3 (Table[2](#T002){ref-type="table"}and[3](#T003){ref-type="table"}), interestingly we found that both the transcriptional and the translational levels of GABABR1 were positively correlated with galectin-3 (Fig [2](#F002){ref-type="fig"}A,B). Even though the biological functions of each individual protein have been well studied, we could not find a report describing the relation between galectin-3 and GABABR1.

GABABRs have been found to play a key role in regulating membrane excitability and synaptic transmission in the brain \[[@B026]\]. GABABRs are G-protein coupled receptors that associate with a subset of G-proteins that trigger cAMP cascades \[[@B026]\]. GABABR subtypes exist; two GABAB-receptor splice variants, GABABR1a and GABABR1b, have been cloned \[[@B027]\], and a new GABABR subtype, GABABR2, does not bind with available GABAB antagonists with measurable potency \[[@B028]\]. GABABR1a, GABABR1b and GABABR2 alone do not activate Kir3-type potassium channels efficiently, but co-expression of these receptors yields a robust coupling to activation of Kir3 channels. GABABR2 and GABABR1a/b proteins immunoprecipitate and localize together at dendritic spines \[[@B028]\]. The heteromeric receptor complexes exhibit a significant increase in agonist- and partial agonist-binding potencies as compared with individual receptors and probably represent the predominant native GABAB receptor \[[@B028]\]. As a previous report also showed that the transcriptional level of GABABR1 was decreased by transfection of galectin-3 small interfering RNA (siRNA) \[[@B011]\], expression of GABABR1 could be regulated by galectin-3. However, reverse immunoprecipitation to validate the interaction between two proteins revealed that galectin-3 did not affect the protein stability of GABABR1 because it formed a complex with GABABR1 (Fig [2](#F002){ref-type="fig"}C).

Gamma-aminobutyric acid (GABA) has been reported to affect cancer development. For example, GABA can be a potential tumor suppressor for small airway-derived lung adenocarcinomas \[[@B029]\]. The GABA agonist nembutal has been reported to be a potent inhibitor of primary colon cancer and metastasis \[[@B030]\]. The GABABR agonist baclofen induced G(0)/G(1) phase arrest of human hepatocellular carcinomas (HCCs), which suggested the possibility of developing baclofen as a therapeutic drug for the treatment of HCCs \[[@B031]\]. Furthermore, stimulation of GABABR signaling has been suggested as a novel target for the treatment and the prevention of pancreatic cancer \[[@B032]\]. However, in our present study, treatment with GABA promoted proliferation of the human colon cancer cell line SNU-C4 (Fig [3](#F003){ref-type="fig"}B). The Korean herbal extract HAD-B not only decreased GABABR1 expression but also reduced proliferation of human colon cancer cells without any expressional change of galectin-3 (Fig [3](#F003){ref-type="fig"}A,B). GABABR activation can lead to down-regulation of the intracellular cAMP level in human cancer cells \[[@B030], [@B032]\]. Downregulation of GABABR1 by HAD-B treatment increased the basal level of intracellular cAMP in SNU-C4 (Fig [3](#F003){ref-type="fig"}C). However, such an increased cAMP was also observed after GABA treatment (Fig [3](#F003){ref-type="fig"}C). The overall findings in the present study were inconsistent with those in previous reports describing the activation of GABABR1 to prevent the progression of a human carcinoma. Nevertheless, our present results showed a link between galectin-3 and GABABR1 in human colon cancer cell proliferation. Galectin-3 regulated GABABR1 expression \[[@B011]\]. Decreased galectin-3 expression reduced not only GABABR1 expression but also the proliferation rate of human colon cancer cells \[[@B011]\]. Even GABA promoted human colon cancer cell proliferation by activating GABABR1 signaling, and the increased proliferation was offset by HAD-B treatment because HAD-B led to galectin-3-independent down-regulation of GABABR1 (Fig. [3](#F003){ref-type="fig"}).

5. Conclusion
=============

Our present study confirmed that GABABR1 expression was regulated by galectin-3. Korean herbal extract HAD-B induced galectin-3-independent down-regulation of GABABR1, which resulted in a decreased proliferation of human colon cancer cells. The therapeutic effect of HAD-B for the treatment of human colon cancer needs to be further validated.
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